Ralph Niven, Chief Scientific Officer at Aerovate Therapeutics, Inc. (AVTE), sold 2,250 shares at $19.00 ($43K) on 2022-09-06, disclosed to the SEC on 2022-09-07.
Scheduled sale ($43k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AVTE | SELL | 2023-12-07 | $75K | — | Filing → |
| AVTE | SELL | 2023-11-27 | $207K | — | Filing → |
| AVTE | SELL | 2023-07-07 | $39K | — | Filing → |